

William Pilcher Fitch, III, M.D.
Urology San Antonio
7909 Fredericksburg Road
San Antonio, TX 78229

EDUCATION :

1964 -1968	University of Texas Austin, Texas Bachelor of Art
1968- 1972	Tulane University Medical School New Orleans, Louisiana Doctor of Medicine
1968 - 1969	University of Texas Health Science Center at San Antonio Affiliated Hospitals San Antonio, Texas Internship
1969 – 1976	University of Texas Health Science Center at San Antonio Affiliated Hospitals San Antonio, Texas Residency

WORK EXPERIENCE:

1976- 8/03/2007	Urology Consultants, P.A. San Antonio, Texas 78229 Group Practice Urology/ Investigator
8/06/2007- Present	Urology San Antonio , PA 7909 Fredericksburg Road, Suite 135 San Antonio, Texas 78229 Group Practice Urologist
8/2007- Present	Urology San Antonio Research, PA San Antonio, Texas 78229 Investigator
1979 – 1980	St. Luke's Lutheran Hospital San Antonio, Texas Chief, Department of Urology
1980 – 1981	San Antonio Community Hospital San Antonio, Texas Chief, Department of Urology

CONT'D WORK EXPERIENCE:

- 1982 - Present Methodist Specialty & Transplant
San Antonio, Texas
Clinical Staff Physician

- 1982 – Present San Antonio Community Hospital
San Antonio, Texas
Vice Chief of Staff

- 1983 – Present San Antonio Community Hospital
San Antonio, Texas
Chief of Staff Elect

- 1984- Present Humana Hospital San Antonio
San Antonio, Texas
Chief of Staff

- 1984- Present Humana Hospital San Antonio
San Antonio, Texas
Chief, Urological Residency Training Program

CREDENTIALS:

- 1978 Diplomat American Board of Urology

HONORS AND AWARDS:

- 2002 The Hustle Award given by the faculty for outstanding contributions to the residency training program.

- 2003 Urology Resident Research Contest winner

- 2003 Texas Urological Society Resident Research Award

- 2003 Spina Bifida Association of America, presentation in Spanish on Vesicoureteral reflux Disease

- 2005 Society of Laparoendoscopic Surgeons Resident Achievement

- 2005 Nominated for the Resident Humanism and Excellence in Teaching Award

PROFESSIONAL AFFILIATIONS:

- American Cancer Society Board of Directors 1977-1980

- American College of Surgeons

- American Medical Association

- American Urologic Association

- Association of American Physicians and Surgeons, Inc.

Bexar County Medical Society International Society for Impotence
Research, Chairman, finance Committee
Kidney Association of San Antonio
Kidney Foundation of South Texas
Planned Parenthood of San Antonio, Board of Clinical Advisors 1976-1990
San Antonio Chapter of Impotents Anonymous – Founder
San Antonio Chapter of Impotents Anonymous – Medical Director
San Antonio Surgical Society
San Antonio urologic Society Secretary – 1977-1978
San Antonio Urologic Society President -1978-1979
Society for the Study of Impotence, Audit Committee, 1995-1996
Guidelines Committee 1998-1999
South Texas Chapter of the American College of Surgeons
Southern Medical Association
Texas Medical Association
Texas Medical Foundation

CIVIC ACTIVITIES:

1978-1979	Leadership San Antonio
1973-1977	Board of Directors, San Antonio, Texas Exes
1976-1977 1980-1983	Executive Council, Texas Exes.
1980-1986 1992	Board of Trustees, Alamo Heights Independent School District.
1982-1983	President, Alamo Heights Independent School District.

Boards and Commissions Task Force, San Antonio Greater Chamber of Commerce
Action Council Member, National Federation of Independent Business
Chamber of Commerce of the United States of America

ACADEMIC APPOINTMENT:

- 1976-1976 Instructor, Department of Surgery Division of Urology The University of Texas Health Science Center at San Antonio
- 1976-1986 Clinical Instructor Department of Surgery Division of Urology The University of Texas Health Science Center at San Antonio
- 1976-1986 Clinical Assistant Professor Department of Surgery Division of Urology The University of Texas Health Science Center at San Antonio
- 1987-1988 Clinical Assistant Professor Department of Surgery Division of Urology The University of Texas Health Science Center at San Antonio
- 1988 Clinical Associate Professor Department of Surgery Division of Urology The University of Texas Health Science Center at San Antonio

AWARDS:

- 1994-Present Listed in Best Doctors in America

BIBLIOGRAPHY:

1. Radwin, H.M., Fitch, W.P. and Robinson, J.R.: A Unified Concept of Renal Trauma. J. Urol 116:20, 1976
2. Radwin, H.M., Fitch, W.P. and Robinson, J.R.: Metstatic Carcinoma of the Ureter. Arch of Surg. III: 874-876, 1976
3. Fitch, W.P.: Reduction Cavernosoplasty. Videourology, Vol. 3, Program 3, 1990
4. Roddy, T. and Fitch, W.P.: Erosion of Inflatable Penile Prosthesis Reservoir into the Bladder. J. Urol. 136:1080, 1986
5. Rosenthal, S.H. and Fitch, W.P.: The Antiherpetic Effect of Phenezine (letter) J. Clin. Psychopharmacology. 7 (2) : 119, 1987
6. Kaufman, J.M., Borgus, F.D., Fitch, W.P., Giller, R.A., Gruber, M.B., Hubbard, J.G., McKay, D.L., Tuttle, J.P. and Witten, F.R.: Evaluation of Erectile Dysfunction by Dynamic Infusion Cavernosometry and Cavernosography (DICCC). Urology 41: 445-451, 1993
7. Cookson, M.S., Phillips, D.L., Huff, M.E. and Fitch, W.P.: Analysis of Microsurgical Penile Revasculariation Results by Etiology of Impotence. J. Urol. 149: 1308-1312, 1993
8. Goldstein, I., Bertero, E.B., Kaufman, J.M., Witten, F.R., Hubbard, J.G., Fitch, W.P., Geller, R.A., McKay, D.L., Krane, R.J., Borges, F.D., Babayan, R.K., Tuttle, J., Gruber, M, Harik, V., and Levenson, S.: Early Experience with First Pre-Connected 3-Piece Inflatable Penile Prosthesis: The Mentor Alpha -1. J.Urol. 1993.
9. Kaufman, J.M., Hatzichrostow, D.G., Mulhall, J.P., Fitch, W.P., and Goldstein, I.: Impotence and Chronic Renal Failure: A Study of the Hemodynamic Pathophysiology. J. Urol 1994.
10. McConnell, J., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, L., Albertsen, P., Roehrborn, C., Nickel, J., Wang, D., Taylor, A., Waldstreicher, J. (For the Finasteride Long-Term Efficacy and Safety Study Group): The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need or Surgical Treatment Among Men with Benign Prostatic

Hyperplasia. New England Journal of Medicine. 38:557-563, 1998

11. Roehrborn, C., McConnell, J., Leiber, M., Kaplan, S., Saltzman, B., Resnick, M., Cook, T., Walderstreicher, J., (For the PLESS Study Group): Serum Prostate Specific Antigen Concentration is a Powerful Predictor of Acute Urinary Retention and the Need for Surgery in Men With Clinical Benign Prostatic Hyperplasia, J. Urol. 163: 13-20. 2000.
12. Roehrborn, C.G., McConnell, J., Bonilla, J., Rosenblatt, S., Hudson, P.B., Malek, G.H., Schellhammer P.F., Bruskewitz, R., Matsumoto, A.M., Harrison, F.H., Fuselier, H.A., Walsh, P., Roy, J., Andriole, G., Resnick, M., Waldstreicher, J., (For the PLESS Group) Serum Prostate Specific Antigen is a Strong Predictor of Future Prostate Growth in Men with Benign Prostatic Hyperplasia. J. Urol. 163:13-20, 2000

ABSTRACT PUBLISHED:

1. Goldstein, I., Bertero, E.B., Kaufman, J.M., Hubbard, J.G., Fitch, W.P., Geller, R.A., McKay, D.L., Krane, R.J., Borges, F.D., Babayan, R.K., Tuttle, J., Gruber, M., Harik, V., Levenson, S.: Multi-Institutional Surgical Outcome Study Utilizing the Mentor Alpha-1 Inflatable Penile Prosthesis. International J. of Impotence Research. 4:A128, 1992
2. Fitch, W.P., Kaufman, J.G., Babayan, R.K., Tuttle, J.P., Witten, F.R., Hubbard, J.G., Gruber, M.B., McKay, D.L., Geller, R.A., Kettlehut, M.: Analysis of Microsurgical Penile Revascularization in Multiple Institutions using Similar Preoperative Selection Criteria. International J. of Impotence Research. 4:R191, 1992
3. Fitch, W.P., Borges, F.D., Kaufman, J.M., Tuttle, J.P., Witten, F.R., Hubbard, J.G., M.B., McKay, D.L., Kettlehut, M., Heine, G.: Effect of Risk Factors Upon Microsurgical Penile Revascularization Postoperative Results. International J. of Impotence Research. 6: D26, 1994
4. Fitch, W.P., Borges, F.D., Kaufman, J.M., Tuttle, J.P., Witten, F.R., Hubbard, J.G., M.B., McKay, D.L., Kettlehut, M., Heine, G.: Analysis of Corporal-Veno-Occlusive Surgery in Multiple Institutions Using Similar Preoperative Selection Criteria. International J. of Impotence Research. 4: P204, 1994
5. Kaufman, J.M., Kaufman, J.L., Fitch, W.P.: Deep Dorsal Vein Arterialization in Arteriogenic Impotence: Use of Dorsal Artery as Neoarterial Source. International J. of Impotence Research. 6:D27, 1994
6. Fitch, W.P.: Patient Acceptance of Vacuum Erection Device and Intracavernosal Injection in the Treatment of Impotence. International J. of Impotence Research. 6:D177, 1994
7. Kaufman, J., Goldstein, I., Tuttle, J., Castellanos, R., Fitch, W.P., Gittleman, M., Albrecht, D., And the Alprostadil Alfadex Study Group: Placebo-Controlled Double-Blind Study of Alprostadil Alfadex for Self-Injection Therapy at Home. International J. of Impotence Research. 8:142, 1996
8. Fitch, W.P.: Seventeen Year Experience Using Inflatable Penile Prosthesis. International J. of Impotence Research. 8:157, 1996
9. Fitch, W.P.: Topical Verapamil for the Treatment of Peyronies Disease. International J. of Impotence Research. 11:S86, 1999
10. Roehrborn, C., Boyle, P., Bergner, D., Gittleman, G. Shown, T., Melman, A., Bracken, B. de Vere White, R., Taylor, A., Wang, D., Waldstreicher, J., (for the PLESS Study Group): Serum Prostate-Specific Antigen and Prostate Volume Predict Long-Term Changes in Symptoms and Flow: Results of a Four Year, Randomized Trial Comparing Finasteride Versus Placebo. Urology 54: 662-669, 1999

11. Bruskewitz, R., Girman, C., Fowler, J., Rigby, O., Sullivan, M., Bracken, R., Fusilier, H., Kozlowski, D., Kantor, S., Johnson, E., Wang, D., Waldstreicher (for the PLESS Group): Effect of Finasteride on the Degree that Symptoms Bother Men and other Health-Related Aspects Associated With Benign Prostatic Hyperplasia. *Urology* 54:670-678, 1999

CLINICAL RESEARCH EXPERIENCE:

1. “A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed-Dose, Parallel Group, 6 Month Comparison Study To Investigate The Efficacy and Safety of the Phosphodiesterase Type V Inhibitor XXXXXXXXX in Males with Erectile Dysfunction
2. “ A Multi-Center, multi-market survey to evaluate the potential enrollment rate using a media based recruitment program in a population of men aged greater than 40 years with mild to moderate signs and symptoms of benign Prostatic hyperplasia.
3. “ A Two Phase, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg XXXXXXXXX in hypogonadal
4. Synthelabo Prospective, observational registry and patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia
5. “ Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Evaluation of the Efficacy and Safety of XXXXXXXXX in the Treatment of the Signs and Symptoms of Benign Hyperplasia
6. “A Two Phase, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-Administration of XXXXXXXXX with 0.4 mg XXXXXXXXX OCAS (TOCAS) Using Urodynamics in Male Subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction
7. “ A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXXXXXXXX 0.5 mg Administered once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer”. Phase III A, International, Multi-Center Study
8. “ A Two Phase, Multicenter Randomized, Two-Dose level and non-inferiority clinical evaluation of Transrectal and transurethral route of Administration XXXXXXXXX for the treatment of BPH
9. “ A Three Phase, Parallel Group, randomized, Double-Blind Placebo controlled Multi-Center trial to investigate the Efficacy, tolerability and safety of XXXXXXXXX Sustained release in subjects with Overactive Bladder syndrome
10. “Long-Term, Open-Label Extension trial for Subjects completing the Phase 3 Trial of XXXXXXXXX for the Treatment of Overactive Bladder syndrome
11. “ A Six Month, Open-Label, Randomized Multi-Center study to evaluate the comparative Efficacy and safety of oral XXXXXXXXX in the Episodic and suppressive treatment of recurrent genital herpes
12. “ A Phase IV, Open-Label, Multi-Center, Flexible Dose Escalation study to Evaluate the Correlation Between event Log Parameters, Self Esteem/Overall Relationships and the efficacy of XXXXXXXXX
13. “A Phase III B, Multi-Dose Multi-Center study in adult males who have successfully completed study XXXXXXXXX and who met the entry criteria for this open-label extension study. Patients

will receive 50 to 100 mgm XXXXXXXXXX daily in unique topical gel formulation.

14. “ Prospective, Randomized, Double-Blind, comparison of XXXXXXXXXX tablets given as two different prophylactic dosing regimens XXXXXXXXXX or Regimen II of post operative infectious complications in patients undergoing transrectal needle biopsy of the prostate
15. “ A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of Evaluate the effect of XXXXXXXXXX in Decreasing the Risk of Prostate Caner. Phase III
16. “Version 1, 2002 / January 2002: A Phase IIIB Randomized, Double-Blind, Multi-Center, Fixed-Dose, Cross Over Study to Investigate the Efficacy and Safety of 20mg of XXXXXXXXXX Given on Demand in Males with Erectile dysfunction and a diagnosis of Diabetes Mellitus and / or Hypertension and / or Hyperlipidemia.
17. Use of Human Serum in the development and Optimization of the PSA Assay
18. “ A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Efficacy and safety study of XXXXXXXXXX for the Prevention of Bone Fractures in men with Prostate Cancer on Androgen
19. “ A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Saety of XXXXXXXXXX 29 mg Administered “On Demand” to Patients with Erectile Dysfunction Following Bilateral, Nerve Sparing, Radical Retropubic Prostatectomy
20. “ A Phase Three Randomized, Double-Blind, Parallel, Placebo-Controlled, study of Evaluate the Efficacy of XXXXXXXXXX When Administered at Specific Time points Prior to Sexual Activity in Men with Erectile Dysfunction.
21. “ A Randomized, Double-Blind, Parallel, Placebo-Controlled study to Evaluate the Efficacy and Safety of XXXXXXXXXX Administered once daily. Open-Label treatment period lasting approximately 1 year will follow the treatment comparison period. The Open-Label period consists of four segments lasting approximately 13 wks each.
22. “ A Randomized, Double-Blind, Placebo-Controlled, Parallel-design, 5 Group, Multi national study to Evaluate the Efficacy, dose-response, and Safety of XXXXXXXXXX, once –daily dosing for 12 weeks in men with Signs and symptoms of Benign Prostatic Hyperplasia. Open-Label Extension: 52 week, 6 Visit study
23. Study of XXXXXXXXXX in women of different demographic characteristics and co-morbidies with stress urinary incontinence: evaluation of efficacy and safety
24. “ A Phase IIB Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of XXXXXXXXXX in Delaying the systemic Progression of Prostate Cancer in Patients with Intermediate to High Risk of Recurrence with rising PSA Levels after Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease
25. “ A Two Year Randomized, Multi-Center, Double-Blind, Parallel Group, Placebo- Controlled study. Phase IV Open-Label: Long Term Efficacy and Safety of XXXXXXXXXX 10 mg on the risk of Acute Urinary retention and the Need for surgery in Patients with Benign Prostatic Hyperplasia
26. “A Multi-Center Randomized, Double-Blind, Placebo-Controlled study Comparing XXXXXXXXXX Transdermal systems versus Tolterodine Long Acting Capsules in Patients with Overactive Bladder.
27. “Double-Blind, Randomized, Parallel Group, placebo-Controlled Trail of XXXXXXXXXX Extended release tablets for treatment of Lower of Urinary Tract Symptoms

28. “ A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Phase 3 trial of single-dose Intravesical XXXXXXXXX as a surgical adjuvant instilled in the early postoperative period in patients undergoing transurethral resection for non-invasive bladder Cancer
29. “Randomized, Double-Blind, Placebo-Controlled, trial of the safety and efficacy of XXXXXXXX in patients with lower urinary tract symptoms due to Benign prostatic Hypertrophy
30. “ A Phase Two, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center, Study to Evaluate the Safety of the Co-Administration of XXXXXXXXX XXXXXXXXX with 0.4 mg XXXXXXXX XXXXXXXX using urodynamics in male subjects with lower urinary tract symptoms and Bladder outlet Obstruction
31. “ A Phase Two, Randomized, Multi-Center, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical trial to study the efficacy and safety of 5, 15, or 25 mg of XXXXXXXX for the treatment of hot flashes following surgical or Medical Castration of Prostate Cancer Patients
32. “A Phase III, Double-Blind, Randomized, Parallel Study evaluating the safety and Efficacy of XXXXXXXX Sublingual in the treatment of Male Erectile Dysfunction
33. “A Phase II Study, Implant for Prostate Cancer
34. “ Multi-Center Phase 111B Open Label Study of Intracavernous Injections of Alprostadil alfadex in the Treatment of Erectile Dysfunction in Patients with Insulin Dependent Diabetes Mellitus
35. “ A brief pilot study to determine the use of oral XXXXXXXX as a therapeutic agent to treat Erectile Dysfunction
36. “ A One year, Multi-Center, Double-Blind, Comparison of the Effects of Once-Daily dosing with Three Dose levels of XXXXXXXX or Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia with six-month untreated follow-up
37. “A Multi-Center, Open label, flexible dose study to Investigate the use patterns of XXXXXXXXX and the ability of Investigators to further Optimize Subject satisfaction with XXXXXXX through customized Instruction.
38. “A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the withdrawal Effects of Chronic Daily Dosing with XXXXXXXX in the Treatment of Premature Ejaculation
39. “A Multi-Center, Double-Blind, study of the Safety and Efficacy of XXXXXXXX Placebo for the Treatment of Hypogonadal Men who are Non-responders to XXXXXXXX
40. “Long Term Effectiveness Trial for AMS Sling Systems MiniArc”
41. “A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXXX vs. XXXXXX in Combination XXXXXX in Patients with Metastatic Hormone-Resistant Prostate Cancer and Bone Metastasis who are Pain-Free or Mildly Symptomatic”
42. “A Phase 3 Randomized, Open-Label Study of XXXXXX in Combination with XXXXXX and XXXXXX Versus XXXXXX and XXXXXX in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain”
43. “TITAN OTR Clinical Trial”
44. “Evaluation of the PCA3 Assay and Algorithms Combining PCA3 Score with Other Factors for the Prediction of Biopsy Outcome and Pathological Stage”

45. "A Phase I, Randomized, Double-Blind, Placebo Controlled Assessment of the Safety , Tolerability and Activity of XXXXX Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection"
46. "A Randomized, Double-Blind, Placebo Controlled, Parallel- Design, Multicenter Study to Evaluate the Urodynamic Effects of XXXXX Once-A-Day for 12 Weeks In Men with Signs and Symptoms of Benign Prostatic Hyperplasia"
47. "An Open-Label, Phase 3 Study of XXXXX Testosterone Gel 2% in Hypogonadal Males"
48. "A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a XXXXX in Comparison with XXXXX in Patients with Overactive Bladder"
49. "Prospective Randomized Double-Blind Study of Sperm Production in Healthy Volunteers Receiving XXXXX or Placebo"
50. "An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients with Locally Recurrent Prostate Cancer After Primary Radiation Therapy"
51. "A Multicenter, Open Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy in Combination with XXXXX Administered Every 3 Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy"
52. "A Phase 3, Multi-Center, Open-Label Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two 6-Month XXXXX Formulations in Subjects with Prostatic Adenocarcinoma"
53. "Performance Evaluation of Optimized Kit Components and Process"
54. "GeneSearch Prostate Methylation Urine (Pro Mu) Assay"
55. "A Randomized, Double-Blind, Placebo Controlled Multicenter Cross over study to Investigate the Pharmacodynamic Profile of XXXXX in Subjects with Pelvic Pain of Bladder Origin"